What I am certain of is that LP did not state they received a provisional letter from the CHM when she spoke at the December 29 ASM. What I am certain of is that Linda stated they were still involved with the MHRA cycles of RFIs. What I am certain of is she did not say they were instead now involved with the CHM process. What I am certain of is that she went out of her way to say she could not predict when marketing authorization would occur.
What I think is highly likely is that there was a CHM meeting that advised regarding DCVax-L’s maa on November 28.
What I think is more likely than not all the way up to highly likely, is that the MHRA shared minor issues with NWBO by around December 5, and that next cycle would likely take us to first week of May (as guideline 2.5 wants a quicker response in such a situation), but hopefully be resolved much sooner, and obviously hopefully not lead to another cycle of RFI minor issues.
Market Data 
Markets 
AI
